IL17RB genetic variants are associated with acamprosate treatment response in patients with alcohol use disorder: A proteomics-informed genomics study

Ming-Fen Ho,Cheng Zhang,James S. Cohan,Mustafa Tuncturk,Robin M. Heider,Brandon J. Coombes,Joanna Biernacka,Irene Moon,Michelle Skime,Ada M Ho,Quyen Ngo,Cedric Skillon,Paul E. Croarkin,Tyler S. Oesterle,Victor M. Karpyak,Hu Li,Richard M. Weinshilboum
DOI: https://doi.org/10.1016/j.bbi.2024.06.007
IF: 19.227
2024-06-11
Brain Behavior and Immunity
Abstract:Acamprosate is a Food and Drug Administration (FDA) approved medication for the treatment of alcohol use disorder (AUD). However, only a subset of patients achieves optimal treatment outcomes. Currently, no biological measures are utilized to predict response to acamprosate treatment. We applied our established pharmaco-omics informed genomics strategy to identify potential biomarkers associated with acamprosate treatment response. Specifically, our previous open-label acamprosate clinical trial...
immunology,neurosciences,psychiatry
What problem does this paper attempt to address?